Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decrease in age-adjusted cerebrospinal fluid beta-secretase activity in Alzheimer's subjects.

Guoxin Wu1, Sethu Sankaranarayanan, Kate Tugusheva

  • 1Alzheimer's Research, Merck Research Laboratory, West Point, PA, USA.

Clinical Biochemistry
|May 21, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Physiotherapy and optimised enteral nutrition in the post-acute phase of critical illness (PHOENIX): a randomised controlled feasibility trial.

EClinicalMedicine·2026
Same author

Advances in artificial metabzymes for molecular metabolism restoration in aging-related diseases.

Chemical communications (Cambridge, England)·2026
Same author

Regional and specialty-specific Medicare reimbursement trends in open and endovascular dialysis access interventions.

Journal of vascular surgery·2026
Same author

KT-YOLO: A multi-convolution kernel collaboration model for dense Hu sheep behavior detection.

PloS one·2026
Same author

Undergraduate dental implantology education in the United Kingdom - looking to the past to plan for the future.

British dental journal·2026
Same author

You Can't Be With Your Patients All the Time-Patient and Staff Views of a Wearable Vital Signs Monitoring System.

Journal of advanced nursing·2026
Same journal

Evaluation of hemoglobin interference thresholds for chemical urinalysis panels.

Clinical biochemistry·2026
Same journal

Integrated genomic and biochemical diagnosis of a novel homozygous start-loss variant in AKR1D1 associated with neonatal cholestasis.

Clinical biochemistry·2026
Same journal

Agreement between POC glucose meters and blood gas analyzers varies across ICU patient populations.

Clinical biochemistry·2026
Same journal

From variability to value: Advancing vancomycin therapeutic drug monitoring toward decision-grade practice through commutability-informed external quality assessment and uncertainty-aware reporting.

Clinical biochemistry·2026
Same journal

Response to the letter to the editor: From variability to value: Advancing vancomycin therapeutic drug monitoring toward decision-grade practice through commutability-informed external quality assessment and uncertainty-aware reporting.

Clinical biochemistry·2026
Same journal

What are the correlates of laboratory productivity in clinical laboratories in the Asia Pacific region?

Clinical biochemistry·2026
See all related articles

A new assay measures cerebrospinal fluid (CSF) beta-secretase-1 (BACE-1) activity. This assay shows decreased BACE-1 activity in Alzheimer's disease patients, suggesting its potential as a diagnostic biomarker.

Area of Science:

  • Biochemistry
  • Neuroscience
  • Biomarker Discovery

Background:

  • Alzheimer's disease (AD) is a neurodegenerative disorder.
  • Beta-secretase-1 (BACE-1) plays a critical role in amyloid-beta plaque formation in AD.
  • Identifying reliable biomarkers for AD diagnosis is crucial.

Purpose of the Study:

  • To develop a novel assay for measuring beta-secretase-1 (BACE-1) activity in cerebrospinal fluid (CSF).
  • To evaluate the potential of CSF BACE-1 activity as a biomarker for Alzheimer's disease (AD).

Main Methods:

  • Developed an enzymatic assay using a specific peptide substrate and a neo-epitope antibody for detecting cleavage products.
  • Characterized the assay's performance, including sensitivity, time, temperature, dose, and pH dependence.

Related Experiment Videos

  • Analyzed CSF BACE-1 activity in a cohort of human subjects, including those with AD and controls.

    • Main Results:

    • The CSF BACE-1 activity assay demonstrated high sensitivity (<1 pM) and specificity, being inhibited by BACE-1 inhibitors.
    • Endogenous BACE-1 in CSF appears to be a c-terminally truncated form.
    • Observed an age-dependent increase in CSF BACE activity and a significant decrease in AD subjects compared to controls.

    Conclusions:

    • A robust and sensitive assay for CSF BACE-1 activity has been successfully developed.
    • CSF BACE-1 activity shows potential as a novel biomarker for Alzheimer's disease.
    • Further validation is warranted to confirm its clinical utility in AD diagnosis.